Liquidia Technologies, Inc. (LQDA) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged Wrongdoings
Bronstein, Gewirtz & Grossman, is investigating potential claims against Liquidia Technologies, Inc. (NASDAQ:LQDA) on behalf of shareholders. The investigation follows Liquidia's announcement on August 19, 2024, that the FDA granted tentative approval for YUTREPIA™ (treprostinil) inhalation powder for treating PAH and PH-ILD in adults. However, final approval is delayed due to a competing product's regulatory exclusivity.
Following this news, Liquidia's stock price fell 30.62%, closing at $9.79 per share. Investors who purchased Liquidia securities are encouraged to assist the investigation. The law firm is representing investors on a contingency fee basis, seeking reimbursement for expenses and attorneys' fees only if successful.
Bronstein, Gewirtz & Grossman sta indagando su potenziali reclami contro Liquidia Technologies, Inc. (NASDAQ:LQDA) per conto degli azionisti. L'indagine segue l'annuncio di Liquidia del 19 agosto 2024, in cui l'FDA ha concesso approvazione temporanea per YUTREPIA™ (treprostinil) polvere per inalazione per il trattamento di PAH e PH-ILD negli adulti. Tuttavia, l'approvazione finale è ritardata a causa dell'esclusività regolatoria di un prodotto concorrente.
In seguito a questa notizia, il prezzo delle azioni di Liquidia è sceso del 30,62%, chiudendo a 9,79 dollari per azione. Gli investitori che hanno acquistato titoli Liquidia sono invitati ad assistere l'indagine. Lo studio legale rappresenta gli investitori su base di compenso contingente, cercando il rimborso delle spese e delle spese legali solo se ha successo.
Bronstein, Gewirtz & Grossman está investigando posibles reclamaciones contra Liquidia Technologies, Inc. (NASDAQ:LQDA) en nombre de los accionistas. La investigación sigue el anuncio de Liquidia del 19 de agosto de 2024, en el que la FDA otorgó aprobación tentativa para YUTREPIA™ (treprostinil) en polvo para inhalación para tratar PAH y PH-ILD en adultos. Sin embargo, la aprobación final está retrasada debido a la exclusividad regulatoria de un producto competidor.
Tras esta noticia, el precio de las acciones de Liquidia cayó un 30,62%, cerrando a 9,79 dólares por acción. Se anima a los inversores que compraron valores de Liquidia a ayudar en la investigación. El bufete de abogados representa a los inversores basándose en una tarifa de contingencia, buscando el reembolso de gastos y honorarios legales solo si tiene éxito.
Bronstein, Gewirtz & Grossman은 주주를 대신하여 Liquidia Technologies, Inc. (NASDAQ:LQDA)에 대한 잠재적 청구를 조사 중입니다. 이 조사는 Liquidia가 2024년 8월 19일 FDA로부터 PAH 및 PH-ILD 치료를 위한 YUTREPIA™ (treprostinil) 흡입 분말에 대해 임시 승인을 받았다고 발표한 후 진행됩니다. 그러나 경쟁 제품의 규제 독점으로 인해 최종 승인이 지연되고 있습니다.
이 뉴스에 따라 Liquidia의 주가가 30.62% 하락하여 주당 9.79달러에 마감했습니다. Liquidia 증권을 구매한 투자자들은 조사를 돕도록 권장됩니다. 이 법률 사무소는 성공할 경우에만 비용 및 변호사 수임료에 대한 보상을 요청하며, 성공 보수에 근거하여 투자자를 대표하고 있습니다.
Bronstein, Gewirtz & Grossman investigue des réclamations potentielles contre Liquidia Technologies, Inc. (NASDAQ:LQDA) au nom des actionnaires. Cette enquête fait suite à l'annonce de Liquidia du 19 août 2024, selon laquelle la FDA a accordé une approbation temporaire pour YUTREPIA™ (treprostinil) en poudre pour inhalation pour traiter la PAH et la PH-ILD chez les adultes. Cependant, l'approbation finale est retardée en raison de l'exclusivité réglementaire d'un produit concurrent.
À la suite de cette nouvelle, le prix de l'action de Liquidia a chuté de 30,62%, clôturant à 9,79 dollars par action. Les investisseurs ayant acheté des titres Liquidia sont encouragés à aider à l'enquête. Le cabinet d'avocats représente les investisseurs sur une base de frais de résultat, cherchant à obtenir le remboursement des dépenses et des honoraires d'avocat uniquement en cas de succès.
Bronstein, Gewirtz & Grossman untersucht potenzielle Ansprüche gegen Liquidia Technologies, Inc. (NASDAQ:LQDA) im Namen der Aktionäre. Die Untersuchung folgt auf die Ankündigung von Liquidia am 19. August 2024, dass die FDA vorläufige Genehmigung für YUTREPIA™ (treprostinil) Inhalationspulver zur Behandlung von PAH und PH-ILD bei Erwachsenen erteilt hat. Allerdings ist die endgültige Genehmigung verzögert aufgrund der regulatorischen Exklusivität eines konkurrierenden Produkts.
Nach dieser Nachricht fiel der Aktienkurs von Liquidia um 30,62% und schloss bei 9,79 US-Dollar pro Aktie. Investoren, die Liquidia-Wertpapiere gekauft haben, werden ermutigt, bei der Untersuchung zu helfen. Die Kanzlei vertritt Investoren auf Erfolgsbasis und beantragt eine Rückerstattung von Kosten und Anwaltsgebühren nur im Falle eines Erfolgs.
- FDA granted tentative approval for YUTREPIA™ (treprostinil) inhalation powder
- Final FDA approval for YUTREPIA™ is delayed due to a competing product's regulatory exclusivity
- Stock price fell 30.62% following the announcement
- Potential legal claims being investigated against the company
This announcement of a legal investigation into Liquidia Technologies is potentially significant. The 30.62% stock price drop following the FDA's tentative approval of YUTREPIA™ indicates substantial market concern. The investigation's focus on potential claims on behalf of purchasers suggests possible securities law violations or misrepresentations.
Key points to consider:
- The FDA's tentative approval, contingent on a competitor's regulatory exclusivity, may have been unexpected by investors.
- The significant stock price decline could imply that the market perceived the news as materially different from prior company communications.
- Investors should monitor for any class action filings and review their own trading history during the relevant period.
While investigations don't always lead to lawsuits, they can impact investor confidence and future disclosures. Shareholders should stay informed but avoid hasty decisions based solely on this announcement.
The market's reaction to Liquidia's FDA update is telling. A
Financial implications to consider:
- Delayed final approval could significantly impact revenue forecasts and cash burn rates.
- Investor confidence may waver, potentially affecting future capital raising efforts.
- The company's competitive position in the PAH and PH-ILD markets may be weaker than previously assumed.
Investors should reassess Liquidia's valuation in light of this setback, considering both the extended timeline to market and potential legal costs. The stock's volatility may persist until there's more clarity on the final approval timeline and any legal outcomes.
NEW YORK CITY, NY / ACCESSWIRE / August 28, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Liquidia Technologies, Inc. ("Liquidia" or "the Company") (NASDAQ:LQDA). Investors who purchased Liquidia securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LQDA.
Investigation Details
On August 19, 2024, Liquidia issued a press release announcing that "the U.S. Food and Drug Administration (FDA) has granted tentative approval of YUTREPIA™ (treprostinil) inhalation powder to treat adults with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD)" but "must await the expiration of regulatory exclusivity of a competing product before final approval can be granted." On this news, Liquidia's stock price fell
What's Next?
If you are aware of any facts relating to this investigation or purchased Liquidia securities, you can assist this investigation by visiting the firm's site: bgandg.com/LQDA. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | info@bgandg.com
SOURCE: Bronstein, Gewirtz & Grossman, LLC
View the original press release on accesswire.com
FAQ
What is the reason for the investigation into Liquidia Technologies (LQDA)?
What happened to Liquidia's (LQDA) stock price on August 19, 2024?
What is the current status of FDA approval for Liquidia's (LQDA) YUTREPIA™?
What conditions is Liquidia's (LQDA) YUTREPIA™ designed to treat?
